PROTAC-Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Proteolysis-targeting chimeras (PROTACs) induce targeted protein degradation via the ubiquitin-proteasome system.
• Histone deacetylases (HDACs) are epigenetic regulators implicated in cancer and neurodegenerative diseases.
• Conventional HDAC inhibitors face limitations like off-target effects and resistance.

Purpose of the Study:

• To review advancements in HDAC-targeting PROTACs.
• To highlight structural optimization, selectivity, and therapeutic applications of HDAC-PROTACs.
• To discuss challenges and future directions for HDAC-PROTAC development.

Main Methods:

• Literature review of recent studies on HDAC-PROTACs.
• Analysis of structural modifications for improved selectivity and efficacy.
• Evaluation of preclinical data for therapeutic potential.

Main Results:

• Development of selective HDAC-PROTACs for isoforms like HDAC3, HDAC4, HDAC6, and HDAC8.
• Demonstration of superior efficacy in preclinical studies for specific HDAC-PROTACs.
• Identification of key areas for structural optimization and selectivity enhancement.

Conclusions:

• HDAC-PROTACs represent a promising strategy to overcome limitations of traditional HDAC inhibitors.
• Further research is needed to address pharmacokinetic challenges and conduct in vivo validation.
• HDAC-PROTACs hold potential for clinical translation in cancer and epigenetic disorders.